OR WAIT null SECS
The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.
July 08, 2026
Article
Catch up on some of the biggest FDA news, clinical trial updates, and featured HCPLive coverage from the first half of 2026.
July 07, 2026
The FDA granted accelerated approval to atacicept to reduce proteinuria in adults with primary IgAN at risk for disease progression
June 03, 2026
Catch up on the key nephrology news, research findings, and expert insights featured on HCPLive throughout May 2026.
June 01, 2026
FDA accepts the BLA for povetacicept in IgA nephropathy, supported by positive phase 3 RAINIER trial data.
May 18, 2026
An expert describes his perspective on sequencing, APRIL inhibition, proteinuria endpoints, and long-term kidney preservation in IgA nephropathy.
May 15, 2026
On IgAN Awareness Day, clinicians highlight earlier diagnosis, dynamic risk stratification, and emerging targeted therapies reshaping care.
April 27, 2026
Stay updated with the latest healthcare breakthroughs, including FDA actions and new topline clinical trial data, in this week’s essential news roundup.
April 21, 2026
Ravulizumab reduced proteinuria by week 10 and met the primary endpoint in the phase 3 I CAN trial in IgA nephropathy.
April 09, 2026
Catch up on nephrology headlines you missed from Q1 2026.
April 08, 2026
HCPLive’s editorial team has compiled 5 of the most informative discussions, along with key data from the WCN.